Compare XBIT & AGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XBIT | AGD |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.8M | 321.4M |
| IPO Year | 2015 | 2006 |
| Metric | XBIT | AGD |
|---|---|---|
| Price | $2.20 | $11.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.5K | ★ 74.4K |
| Earning Date | 11-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $30.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.09 | $10.41 |
| 52 Week High | $3.44 | $13.98 |
| Indicator | XBIT | AGD |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 41.11 |
| Support Level | $2.16 | $11.37 |
| Resistance Level | $2.48 | $12.27 |
| Average True Range (ATR) | 0.04 | 0.18 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 66.67 | 27.69 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors, among others.